Disease relevance of Rubidomycin

• Daunorubicin hydrochloride, particularly, is known to cause renal failure in experimental animals [1].
• Especially increase in CK activity, measure for cardiac toxicity, was significantly altered in animals that were treated with rubomycin-containing liposomes [2].
• Escherichia coli K12 cells treated with Ca2+ at 25 degrees or 37 degrees C in presence of CCCP became permeable for transforming plasmid and transfecting DNAs and DNA-binding antibiotic actinomycin C (AmC) and rubomycin (Rm) at room temperature [3].
• Fourteen patients with advanced measurable colorectal cancer were treated with daunorubicin hydrochloride (DNR) [4].
• The central aim of this present study was to modify the reverse evaporation process, such that an enhanced entrapment, with increased storage stability and prolonged release, could be achieved, and to translate these advantages to increased therapeutic efficacy of daunorubicin hydrochloride on Dalton's ascitic lymphoma [5].

High impact information on Rubidomycin

• Different serum enzyme levels (creatine kinase, CK; lactate dehydrogenase, LDH; alanine amino-transferase, ALAT; aspartate aminotransferase, ASAT) were determined after treatment of mice with rubomycin in free or liposomally encapsulated form [2].
• The comparison of experimental data with the predictions of both homogeneous and "shell-and-core" models demonstrates the impossibility of using these models for adequate description of the rubomycin sorption kinetics on the sorbent, BDM-12 [6].
• Analysis of rat bone marrow by flow cytometry following in vivo exposure to cyclohexanone oxime or daunomycin HCl [7].
• The efficiencies of transformation and transfection, however, were by 1-3 orders of magnitude lower compared to cells, treated with Ca2+ at 0 degree C, though both recipients did not differ significantly in their susceptibility to AmC and Rm [3].
• Amine derivatives were obtained by the reductive amination of aromatic aldehydes with daunorubicin hydrochloride [8].

Chemical compound and disease context of Rubidomycin

• Comparative toxicity of carminomycin, rubomycin and adriamycin in mice and experience with carminomycin in spontaneous tumors of dogs [9].
• A set of multidrug resistant (MDR) murine leukemia P388 sublines processing 30-50-fold mdr1 gene amplification was obtained as a result of experimental chemotherapy with rubomycin, ruboxyl, vinblastine, vincristine, or combination of rubomycin and vincristine [10].

Biological context of Rubidomycin

• Pharmacokinetics of a spin-labeled rubomycin analog [11].
• Apoptosis and sensitivity of U937 to daunoblastina (DNR) were quantified by DNA ladder detection and trypan blue exclusion assays, respectively [12].
• Cytogenetic and kinetic analyses showed that variants of Fisher lymphadenosis L-5178 resistant to bruneomycin and rubomycin C retain sensitivity to N-nitrosomethylurea (NMU) [13].

Anatomical context of Rubidomycin

• Rubomycin loaded erythrocytes in the treatment of mouse tumor P388 [14].
• Administration of empty liposomes immediately before liposomal Daunoblastin did not result in better antineoplastic activity but yielded higher leukocyte values [15].
• The cytostatic anthracycline antibiotic daunomycin hydrochloride led to the development of plastic myocardial insufficiency characterized by impaired intracellular regeneration of cardiomyocytes and progressive involution of cytoplasmic structures [16].
• Regenerative and plastic myocardial insufficiency characterized by impaired intracellular regeneration, progressive involution and apoptosis of cardiomyocytes associated with selective cardiotoxic effect of anthracycline antibiotic rubomycin is accompanied by enhanced proliferative and functional activities of fibroblasts and other stromal cells [17].
• The comparison of the viability of L and L-53 cells in the presence of Rubomycin C and Lycurim showed a resistance of the L-53 cells to Rubomycin C, while the effect of Lycurim was the same on both cell lines [18].

Associations of Rubidomycin with other chemical compounds

• Pharmacokinetics of a spin-labeled analog of rubomycin (ruboxyl) was studied [11].
• The competitive interaction with DNA of daunorubicin (DR), being present in the clinical anti-tumor drug daunoblastina, and the fluorescence probe ethidium bromide (EB) has been studied by parallel-factor analysis (PARAFAC) and full-rank parallel-factor analysis (FRA-PARAFAC) of a fluorescence excitation-emission three-way data array [19].

References